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SUMMARY
Identified 50 years ago, mesenchymal stromal/stem cells (MSCs) immediately generated a substantial interest among the scientific
community because of their differentiation plasticity and hematopoietic supportive function. Early investigations provided evidence
of a relatively low engraftment rate and a transient benefit for challenging congenital and acquired diseases. The reasons for these
poor therapeutic benefits forced the entire field to reconsider MSC mechanisms of action together with their ex vivo manipulation
procedures. This phase resulted in advances in MSCs processing and the hypothesis that MSC-tissue supportive functions may be
prevailing their differentiation plasticity, broadening the spectrum of MSCs therapeutic potential far beyond their lineage-restricted
commitments. Consequently, an increasing number of studies have been conducted for a variety of clinical indications, revealing
additional challenges and suggesting that MSCs are still lagging behind for a solid clinical translation. For this reason, our aim was
to dissect the current challenges in the development of still promising cell types that, after more than half a century, still need to
reach their maturity. STEM CELLS TRANSLATIONAL MEDICINE 2019;8:1135–1148
SIGNIFICANCE STATEMENT
This article highlights mesenchymal stromal/stem cell (MSC) strengths and overall weaknesses in order to contribute to the
achievement of a better awareness of challenges related to MSC developments that should be taken into account in future
MSC-based therapeutics.
MESENCHYMAL STROMAL/STEM CELLS IN LAST CENTURY
Mesenchymal stromal/stem cells (MSCs) were identified more
than 50 years ago, and these originally elusive progenitor cells pre-
sent in bone marrow (BM) immediately attracted the interest of
scientists attempting to determine the existence of multifunctional
cells in a tissue known to possess hematopoietic stem cells (HSCs).
That was the case for Friedenstein, whose group, in 1966, reported
the existence of BM cells capable of generating hematopoietic
cells, fibroblastic reticular cells and bone in vivo [1]. In the begin-
ning, the nature of those differentiating cells was unclear. How-
ever, a few years later, the same authors described a rare
population of BM cells that adhered to plastic after in vitro
seeding, creating a heterogeneous multitude of spindle-shaped
cells. In those days, cells were grown without any specific nutri-
tional requirements except for the addition of fetal bovine serum
(FBS). The definition of that time was “mechanocytes” due to the
tendency of these cells to generate bone when mechanically stim-
ulated, suggesting that a physical stimulus could induce differentia-
tion [2].
In parallel, Dexter et al. observed that human BM cells, after
in vitro seeding, formed a heterogeneous adherent cell layer com-
posed of macrophages, endothelial cells, and fibroblasts often
characterized by preadipocytic features [3]. They further deter-
mined the functional character of these cells in an in vitro envi-
ronment, revealing their capacity to support and maintain HSCs,
and for this reason, they defined this population as stromal cells.
It was in 1988 that Owen and, once again, Friedenstein demon-
strated that these stromal elements were capable of producing
colonies with self-renewal and multipotency [4]. They additionally
described that factors added to the medium were able to activate
specific differentiation pathways, in that case, toward a bone
commitment. Thus, stromal function and stemness could overlap,
at least according to those early in vitro experiments.
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PERSPECTIVES
Around the same years, Caplan proposed MSCs as mesen-
chymal progenitors capable of generating mesodermal restricted
lineages [5], and later on, several groups published relevant data
on the differentiation capacity of MSCs providing evidence of
their plasticity even across ontogenic lineages [6, 7]. With these
data in mind, clinicians and scientists moved ahead, and the dif-
ferentiation capacity of MSCs was challenged in vivo in preclini-
cal models and in early clinical studies of tissue regeneration [8].
A much higher level of stemness has then been attributed to
MSCs, up to pluripotency, with almost infinite proliferation and
differentiation capacity, with a terminology shift to multipotent
adult progenitor cells (MAPCs) [9, 10]. Further in vivo investiga-
tions in a variety of regenerative medicine approaches have rev-
ealed a suboptimal performance with a low engraftment rate
that was still associated with some therapeutic impact [11].
Thus, investigators wondered whether the word “stem” would
still be fitting with MSCs biological properties and how MSCs
would exert (lasting) therapeutic benefits in vivo [12]. In this
context, scientists have been more focused on biological func-
tions more attributable to stromal functions than to multi-
potency [13, 14].
Essentially, we could summarize the relationship between
stemness and “stromalness” in a sort of diagram (Fig. 1). In the
late 1960s and 1970s there was a progressive increase in data
regarding the proliferation and differentiation capacity of MSCs
with the stemness concept that reached maturity in the 1980s.
This advancement peaked around 2000 and then decreased. This
left more room for MSCs “stromalness” to grow, which started
with the hematopoietic supportive stromal cells described by
Dexter et al., has progressively increased involving the release of
a variety of growth factors, chemokines, cytokines, and more
recently extracellular vesicles (EVs) [3, 15–18] The capacity to
release molecules has been further empowered by the provoca-
tive theory that MSCs could actually be Medicinal Signaling Cells,
keeping the acronym but changing a paradigm [19]. Nowadays,
we may state that stemness and “stromalness” coexist at differ-
ent levels, influencing each other in a reciprocal manner. The
challenge is to understand the extent of the two in MSC prepara-
tions accounting for variability in tissue sources, in donor-related
issues (including age, disease, gender, lifestyle), in the ex vivo
culture conditions (isolation tools, culture media, population
doublings [PD], dissociation reagents) and in the delivery strate-
gies (fresh versus frozen product, transportation buffer, injection
routes, and injection tools).
LEARNING FROM MORE THAN 50 YEARS OF MSC
INVESTIGATIONS
Several properties have been attributed to MSCs in the last
50 years of research, even if basic concepts originally developed
by Friedenstein and Dexter still have pivotal roles. MSCs can now
be isolated from different sources, and MSC populations have
been described in a variety of sources including adipose tissue
(AT), skin, cord blood, Wharton jelly, placenta, amniotic fluid,
liver, bile ducts, lung, and teeth [20]. This wide distribution of
MSCs throughout the body has been quite surprising, and it is
supported by the concept indicating that MSC-like populations
can virtually reside in all organs, since they are connected to ves-
sels as pericyte populations [21].
The multiplicity of sources of MSCs has been accompanied
by the emergence of novel tools for their ex vivo isolation and
the following in vitro expansion and manipulation for thera-
peutic purposes. These tools include isolation reagents and
devices, specific culture media, and ancillary reagents whose
introduction both at the academic and industrial level have
introduced innovative protocols on how to efficiently isolate
MSCs, allowing the transfer of this technology to large-scale
expansion and facilitating the translation of preclinical findings
into the clinic. For example, focusing on BM-derived MSCs, it
is now established that starting from 20 ml of marrow aspirate
shipped overnight from the clinic to the cell manufacturing
site, MSCs can be isolated and amplified to up to hundreds of
millions of cells in less than 1 month. Cells can then be
shipped back to the operating room for surgical implantation
alone or even in combination with biomaterials for skeletal
disorders [22, 23].
New isolation methods have also been changing the para-
digm of plastic-adherent MSCs, and a source of MSCs has also
been described in the nonadherent culture fraction, called non-
adherent mesenchymal progenitors (NAMP) [24–26]. This cell
fraction, dependent on basic fibroblast growth factor (bFGF)
action, can be expanded as a cell suspension, possibly rep-
resenting a specific population of early progenitors with a less
committed phenotype compared with the plastic-adherent MSCs
[27, 28]. According to these protocols, using both BM and fat as
resources, it is possible to isolate from NAMP an adherent frac-
tion with similar proliferation and differentiation potential as
MSCs [29]. Although these protocols need to be standardized,
these data indicate how cell culture conditions could iso-
late/rescue progenitor cells with different potential, virtually
representing a complementary cell source in clinical
applications.
Beside the matter of quantity, in the last decades, MSCs
were better characterized from several points of view. Although
MSCs still lack a single specific surface marker, panels of markers
guiding their identification have been proposed [30–32]. Other
features have been described and are now shared by the scien-
tific community, such as genomic, epigenetic, secretomic, and
proteomic profiling [33–36]. More recently, the release of
exosomes, a smaller EV fraction, has been outlined as a relevant
biological mechanism in driving tissue regeneration [37].
Figure 1. Relationship between stemness and “stromalness.” Mes-
enchymal stromal/stem cell (MSC) stemness has been supported by
a progressive accumulation of data regarding their proliferation and
differentiation capacity since the late 1960s, reaching its peak
around 2000. This feature then decreased slightly, leaving more
room for another MSC feature, here defined as “stromalness,” based
on tissue-supportive functions (such as hematopoietic stem cell-
supportive function), which progressively increased involving the
release of a variety of growth factors, chemokines, cytokines and,
more recently, extracellular vesicles.
© 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press
STEM CELLS TRANSLATIONAL MEDICINE
1136 Challenges for MSCs in the Clinic
Although these properties are sufficient for defining a correlation
between phenotype and stromal/stem cell functions it still has
to be convincingly demonstrated; however, it represents a foun-
dation on which more specific criteria to better identify MSC
properties could be developed.
Cell availability and characterization now allow investiga-
tors to introduce MSCs in various disease models with promis-
ing although sometimes disappointing outcomes, not much
related to the safety of the procedures rather than the efficacy
endpoints to be reached. Essentially, we found ourselves in
paradoxical situation of being able to amplify billions of MSCs
and infuse them in a variety of clinical applications together
with the difficulties in dissecting what is/are the precise mech-
anism/s of action (MoA) for a defined clinical indication [38].
The task to identify MSCs MoA is itself a challenge and,
despite being compared with “classic” drugs, these cells are a
living entity with metabolic activity, receptors, and the capac-
ity to respond to environmental stimuli, influencing their ther-
apeutic actions. This so-called “plasticity” has the predicted
value to make MSCs a sort of “chameleon” in different con-
texts, with the capacity to adapt their ability to pathological
conditions and thereby exert a therapeutic benefit [14].
However, this plasticity is difficult to follow in the labora-
tory, and the complexity of mimicking those pathological condi-
tions ex vivo is the most critical aspect in predicting the precise
MoA of MSCs in vivo and therefore in the development of
effective potency assays [39]. This difficulty is also related to
the preclinical animal models that have been introduced to
demonstrate the efficacy of MSC-based strategy. Generally, ani-
mal models are developed to resemble human diseases, but
they have limitations in the different immunological and sero-
logical (chemokines, cytokines) contexts, which may not be ideal
in triggering the desired MSCs phenotype in vivo, not only
under xenogeneic conditions but also in syngeneic models, due
to the difference between human and animal MSCs [40].
TISSUE SOURCE MATTERS
The early origin of MSCs has been limited to BM for a long time,
despite that adipose-derived progenitors have been described
since the 60s [41, 42]. Nowadays, MSC-like populations can be
isolated from a variety of sources and each has its peculiarity
with early comparative analyses reporting differences based on
the tissue of origin as summarized in Table 1 [43].
BM was long regarded as the major source of MSCs [1].
However, BM collection requires an invasive bone harvest pro-
cedure that may also be accompanied by pain and risk of infec-
tion [44]. In addition, since MSC precursors account for only
0.001% to 0.01% of the overall cell population, allowing the iso-
lation of only 60–600 cells per ml of BM aspirate, there is a need
to harvest a large amount of raw material along with extensive
ex vivo culture to obtain sufficient cell numbers for clinical appli-
cations in humans [7]. BM-derived MSCs retain substantial
multilineage differentiation, although mesodermal restricted
and coupled with a low proliferation capacity compared with
other MSC types [43]. BM-MSCs have a longer doubling time
(DT, approximately 60 hours) compared with such cells from
other tissue sources [45]. This is also associated with a quite
heterogeneous cell size with large flat cells together with small
round cells and spindle-shaped cells (Fig. 2) and the appearance
of senescence landmarks, since relatively early passages are
involved, even as of passage 7 [46, 47]. Thus, MSCs aging has an
important impact on the effectiveness of BM cells, influencing
their number, maximal lifespan and differentiation potential.
These properties make cells certainly useful for autologous
transplantation, where immunity should not interfere with the
regenerative properties of the cells and considering that alloge-
neic use may be associated with very relevant ex vivo expansion
to reach a billion-cell level, which may be difficult in this case.
However, autologous use is suffering from conditions associ-
ated with marrow toxicity, such as during major silver sulfadia-
zine toxicity, as a result of sepsis, during chemo- or radiotherapy
[48–50]. In view of the clinical application of MSCs, accumulated
evidence suggests that the bioactive secretion of MSCs is the
main reason for their therapeutic benefits, improving the angio-
genic activity of endothelial cells and promoting blood restora-
tion. Numerous putative angiogenic proteins have recently been
identified in EVs derived from MSCs that contribute to cell-to-cell
communication to control angiogenesis during wound healing.
BM-MSCs are characterized by a significant paracrine function
and could be preferred in clinical applications for therapeutic
angiogenesis due to the angiogenic factors, growth factors, and
cytokines discovered in their secretome [51–53].
Over time, a number of other tissues have been identified
as alternative sources of human MSCs. Nowadays, MSCs can
Table 1. Comparison of mesenchymal stromal/stem cells (MSCs) from different sources with reference to different parameters: bone
marrow-derived MSCs, adipose tissue-derived MSCs, umbilical cord-derived MSCs, dental pulp stem cells, and endometrial MSCs
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be isolated from multiple tissues, including AT, perinatal tis-
sue, dental tissue and decidual endometrial blood [54].
AT-MSCs were identified early in the 1960s, which were
then characterized by Zuk et al. in 2001 [55, 56]. AT-MSCs
started to be used in regenerative medicine (RM), as an alterna-
tive or in addition to BM-MSCs [31]. Subcutaneous AT repre-
sents an abundant source of AT-MSCs [57], and the average
increase in body mass index (BMI) easily allowing to find this
material, normally discarded [58]. Compared with BM-MSCs,
they are superior candidate cells for autologous cell transplanta-
tion, as they can be isolated from the biological material
harvested by less invasive procedures as the liposuction,
lipoplasty, or lipectomy [59]. AT is not only easier to harvest,
but it also has a better yield with 500 times more MSCs precur-
sor cells than from an equivalent amount of BM [60, 61]. For
these reasons AT-MSCs are attractive candidates for therapeutic
use. Like BM-MSCs, AT-MSCs can be easily expanded in culture,
and they have higher proliferation capacity, showing shorter DT
by approximately 20 hours. Although still related to the body
region from where they originate and unlike BM-MSCs, AT-
MSCs can be cultivated up to passage 8 without any sign of
senescence [45, 46], even if passages may not precisely reflect
the replicative age of MSCs [62]. There is evidence that adipo-
cyte progenitors vary on the basis of individual adipose depots
and depending on the age, sex, and body weight of the individ-
ual, location and type of fat tissue, tissue collection method,
and culture conditions [63–65]. Furthermore, recent studies
suggest that the heterogeneous mixture of cells obtained after
digestion of AT, contains subpopulations of stem cells and more
committed progenitor cells, such as dedifferentiated endothelial
cells, smooth muscle cells, and pericytes. However, the hetero-
geneity of cultured AT-MSCs seems to be limited after plastic
adhesion, when they appear morphologically smaller than BM
cells [63]. Although AT-MSCs may represent a valid alternative
to BM-MSCs, able to solve issues related to the cell quantity
required for therapies, their “innate” tendency for adipose dif-
ferentiation rather than skeletal tissue development has to be
seriously considered [66, 67]. Furthermore, AT-MSCs show a
significantly lower secretion of proangiogenic molecules and
cytokines compared with BM-MSCs, with a possible impact on
their therapeutic benefit, such as the reduction of inflammation
[68, 69]. This may also be related to the different in vivo envi-
ronments of the respective tissue of origin: BM is abundant
with a variety of hematopoietic and endothelial cells, whereas
AT is predominantly filled with adipocytes.
MSCs can also be isolated from birth-associated tissues,
including placenta, amnion, umbilical cord (UC), and umbilical
cord blood (UCB). They are readily available, thus avoiding inva-
sive procedures or ethical issues and offer an advantage not
found in adult tissue because their harvest avoids the potential
problems related to age. Moreover, they show improved prolif-
eration ability, lifespan, and differentiation potential compared
with BM-MSCs and AT-MSCs [43, 70]. More interestingly, the
possibility to have a large amount of cord allows a rapid isola-
tion of the MSCs population for allogeneic cell-based regenera-
tive medicine applications [71]. UCB-MSCs from a single donor
are sufficient to generate 1 × 109 cells within passage 3–4 in a
cell factory system, and furthermore, they can be expanded
over 16 passages with retention of normal karyotype and
without any sign of senescence or variation in cell morphol-
ogy [72, 73]. However, there are some drawbacks linked to the
successful isolation and expansion of UCB-MSCs, mainly due to
the low frequency of MSC clones in particular when compared
with UC, a rich source of highly proliferative MSCs characterized
by: a higher isolation yield (5 × 104–5 × 105 cells from 1 cm3 of
UC tissue), higher frequency of colony-forming unit (CFU)-F and
shorter DT (24 hours) compared with BM-MSCs and a homoge-
nous phenotype of adherent, spindle-shaped fibroblast-like cells
in primary culture [74–76]. The therapeutic effect of the secret-
ome from UC-MSCs is currently under investigation, and it
appears to be rich in angiogenic factors that make it similar and
competitive compared with the BM-MSC secretome [77]. Fur-
thermore, stem cell banks offer the opportunity to cryopreserve
cord tissue as a possible source of MSCs for future autologous
uses, pending the possibility to isolate cells after long-time
freezing. However, there are controversial opinions approxi-
mately cryopreserved cord tissue. On one side, it could circum-
vent early MSCs isolation and related manipulations before
freezing [71], on the other the isolation of living MSCs from
thawed cord tissue is not always successful, due to the differ-
ences in exposure to cryoprotectant between the outer and
inner parts of the tissue, resulting in cell death [78, 79].
MSCs can be easily isolated from various dental tissues
including dental pulp, apical papilla, dental follicle, human
exfoliated deciduous teeth, periodontal ligament, gingival, and
tooth germ-derived cells [80]. Dental pulp stem cells (DPSC)
are increasingly being recognized as a viable cell source for
regenerative medicine. Stromal cells represent roughly 10% of
dental pulp cells and display multipotency, and interestingly,
they exhibit a higher proliferation rate in vitro compared with
BM-MSCs [81]. Current studies indicate that they maintain
their high rate of proliferation even after extensive subculture
with a DT of 30 hours [82]. Their proliferative and multilineage
capacity as well as accessibility of sources makes them attractive
for therapeutic purposes. However, they show some limitations
due to the intrinsic nature of dental tissue that does not undergo
continuous remodeling as shown in bone tissue. Therefore, den-
tal tissue-derived MSCs may be more committed or restricted in
their differentiation potency in comparison to BM-MSCs, as
Figure 2. Mesenchymal stromal/stem cells (MSCs) heterogeneity.
Representative photomicrograph showing the variety of cell sizes
and shapes in bone marrow MSCs. There are tripolar-shaped cells
(yellow), long spindle-shaped cells (orange), small round cells
(red), short spindle-shaped cells (blue), and flattened enlarged
cells (black). Contrast Ph1 ×100 magnification, observer A1 (Zeiss).
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demonstrated by their weaker chondrogenic and adipogenic
potential [83]. MSC populations in dental pulp are heteroge-
neous and demonstrate differences in proliferation rate and dif-
ferentiation capacity, depending on donor age, also detected
between DPSC populations from donors within a similar age
range and even between cell populations from the same patient.
At early passage (7–8 PD), all DPSC appear morphologically simi-
lar, with long spindle shape, whereas at later stages, cells appear
larger and more stellate with prominent stress fibers, but the
onset of the senescent phenotype is highly variable [84].
Although DPSC show an efficient secretion of bioactive mole-
cules, the secretion of proangiogenic factors is lower compared
with BM-MSCs and AT-MSCs. However, they secrete significantly
larger amounts of chemokines and neurotrophins implicated in
neuroprotection and neural supportive properties in response to
injuries and pathologies of the nervous system [85, 86]. Autolo-
gous transplantation remains the most common practice for
dental MSC applications, even if it shows serious limitations
because it requires the extraction of remaining teeth. Further-
more, donor age should also be taken in consideration, since
proliferation, migration, and differentiation capacity of these
cells decrease with donor age [87]. Thus, one of the main chal-
lenges in autologous clinical applications of this MSC type is the
limited cell availability, where paradoxically, the patient would
need more of these cells. Tooth banking could ensure the cryo-
preservation of cells and tissues for future need in autologous
transplantation, but it is not currently a popular practice.
Since 2004, a small population of clonogenic stromal cells
with typical adult stem cell properties of self-renewal, high
proliferative potential, and multilineage differentiation capacity,
although less robust than BM-MSCs, was identified in endome-
trial MSCs (eMSCs) [88]. They are normally obtained from hyster-
ectomy tissue and uterine biopsy or more easily from menstrual
blood, which is considered an attractive source of MSCs for
regenerative medicine because of its relative ease of acquisition
with minimal morbidity. Obtaining eMSCs from menstrual blood
uses body waste and requires no invasive procedures using a
menstrual cup over several hours on days 2–3 of the menstrual
period, providing sufficient cell number [89]. Isolation yield is vari-
able, but 2–4 × 106 nucleated cells per milliliter of initial blood
can be isolated, of which approximately 0.2%–0.3% are colony-
forming cells expressing standard mesenchymal markers [90].
Adherent cells cultured from menstrual blood rapidly expand with
a DT of 27.6 hours, undergoing 25–30 PD without any sign of
senescence until passage 26 [91–93]. They show the typical mes-
enchymal appearance, being fibroblastoid-like, spindle-shaped
cells, although some endothelial-like cells can appear in the very
early passages, disappearing at passage 3 when the cell popula-
tion becomes rather homogeneous [89, 94]. The secretome of
eMSCs shows an immunomodulatory activity and when com-
pared with the exosome fractions of different human MSC
sources, eMSC exosomes show superior effects on neuritic out-
growth, while their proangiogenic effect is not well documented
[95]. Despite that eMSCs can be isolated from women of all ages
irrespective of hormonal status or treatments, they represent a
gender-related source, and the woman’s age may influence cell
proliferation, impacting their potential autologous use [96, 97].
Although there is some evidence that BM cells contribute to a
small population of endometrial epithelial and stromal cells,
eMSCs are a novel and still not completely understood population
of mesenchymal progenitors, which still lack specific markers.
Thus, despite similarities, MSCs derived from such a wide
variety of human tissues have different functional proper-
ties [70, 72]. More than 10 years ago, under the umbrella of
the International Society for Cellular Therapy (ISCT), we pro-
posed a series of basic criteria with the aim to better define
MSCs in the context of preclinical investigations [30]. Although
the simplicity of the approach favored the recognition of these
minimal criteria, even beyond the original scope of the article,
the increasing complexity of the MSCs field is now calling for
updated criteria to define these cells. Although basic features
(fluorescence-activated cell sorting [FACS] analyses, morphology
and basic differentiation in vitro) may help in distinguishing
MSCs from other cell types, they are certainly unable to snap-
shot the current predicted in vitro/in vivo performance, calling
for novel ways to characterize MSCs. Theoretically, this has to be
achieved for each specific MSC type considering the originating
tissue and addressing macroscopic features, phenotypic markers,
defined differentiation properties, and specific molecular finger-
prints as well as specific secretory potential either as released
soluble molecules or as exosomes. An attempt toward an
updated MSC characterization in a tissue-specific manner has
been already proposed, and ISCT in collaboration with other soci-
eties has dissected adipose-derived-MSC properties, combining a
variety of phenotypical markers, functions, and differentiation-
related genes [31].
MSC DONOR-RELATED VARIABILITY MATTERS
An autologous MSC source is widely used in cell therapy [98].
However, several studies have revealed donor-related variations,
caused by gender, BMI, donor site, age, and diseases. The recog-
nition of the variability in biological function has a relevant
impact either in an autologous setting, where MSCs implantation
would not be followed by the desired benefit or most impor-
tantly in an allogeneic context where apparently healthy and
functional MSCs may be actually dysfunctional for yet unclear
reasons. Although the identification of these donor-related varia-
tions appears complex, their investigation and discovery could
be key in identifying specific MSC donors for particular diseases
to ultimately avoid failure in both early and late clinical trials. In
the attempt to identify these factors, we have recently reported
the development of an assay capable of predicting bone forma-
tion [99]. According to this approach, a gene signature has been
identified in relationship with in vitro and in vivo functional
assays to be ultimately compared with the outcome of clinical
investigations.
A study performed in a rat model revealed the superiority
of female MSCs in reducing lung inflammation compared with
male MSCs [100]. Women are more exposed to hormonal vari-
ations, such as a decrease in circulating estrogen levels in
menopausal status, which has been shown to be responsible
for loss of osteogenic potential of stem cells [101]. Gender var-
iability was also confirmed for AT-MSCs by Ogawa et al. who
showed a greater level of Peroxisome Proliferator Activated
Receptor-Υ2 (PPAR-Υ2), a marker of adipogenesis, in cells
harvested from female mice compared with male mice [102].
Although there are conflicting reports approximately the
effect of aging on MSCs performance, disparate studies have
reported age-related changes in MSCs, such as loss of prolifera-
tion and differentiation potential, increase in senescence and
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loss of in vivo bone formation [103]. MSCs from older patients
show a reduction in superoxide dismutase activity and an
increase in nitric oxide and reactive oxygen species, which lead
to oxidative damage in MSCs and consequently apoptosis and
senescence. Moreover, aged MSCs are characterized by an
upregulation of both p53 and p21, well known for their pro-
apoptotic activity, and a decline of Notch-1 receptor, probably
involved in bone differentiation [103]. A substantial influence of
donor age is also reported for CFU-f number, which decreases in
older patients, and for molecular markers. In particular, Candini
et al. identified seven miRNAs differentially expressed in young
and old groups, among which miR-196a was upregulated in aged
MSCs, whose level correlated inversely with ki67. The substantial
interest shown in these data is due to the involvement of miR-
196a in the regulation of the homeobox (HOX) gene and the
essential role of the HOX family in skeletal formation [36,
104, 105].
As MSCs are the basis of tissue regeneration therapies,
altered cell functionality in elderly patients may compromise
the efficacy of autologous approaches. With an increase in the
aging population, older patients are becoming the most com-
mon target for cell therapies, and it is important to investigate
how much donor age is a critical factor in achieving expected
results [106]. Alternative strategies are necessary, such as a
younger MSCs bank for later use, and preserving progenitor
cells maintaining their regenerative potential. The previous
association between HOX expression and aging has been con-
firmed by the lower levels observed in adult groups. When
MSCs are modified to overexpress HOXB7, there is an
increased level of ki67 and bFGF, which is involved in progeni-
tor self-renewal, proliferation, differentiation, and osteogene-
sis [107]. These proof-of-concept findings can open the way to
novel strategies, particularly for skeletal disorders, and offer
new explanations for tissue engineering failures.
The efficacy of autologous cell therapy in the treatment of
several diseases has to deal with the intrinsic impact that the
diseases themselves may have on MSCs regenerative potential.
Systemic and more focal diseases can affect the MSCs com-
partment in multiple ways, possibly restricting the effective-
ness of autologous treatments. Systemic diseases may affect
autologous cell-based treatment, such as diabetes or cardio-
vascular diseases (CVDs).
In particular, type 2 diabetes (DM2) is a chronic metabolic
disease that represents a major risk factor for the development
of vascular disease, causing a high rate of mortalities globally. It
has been reported that DM2 has adverse effects on MSCs func-
tion, inhibiting the angiogenic ability of MSCs through the
downregulation of pro-angiogenic factors. Furthermore, BM-
MSCs from diabetic patients show hampered paracrine secre-
tion and an increased propensity to differentiate into adipo-
cytes [108, 109].
Another global burden is represented by CVDs, one of the
leading causes of death in the Western world [110]. Aging is
the main driver of CVD progression, inducing vascular changes
and reducing regenerative potential of stem cells. In turn,
CVDs also affect the progenitor cell compartment, causing
increased senescence, reduced proliferation, and regenerative
potential in MSCs [111]. This could represent a limitation for
autologous cell therapy in CVDs, which may be solved by using
allogeneic MSCs, selected on the basis of age and
comorbidities.
Furthermore, BMI has been reported to have an effect on
the differentiation and proliferation abilities of adipocytes
[112]. In obese individuals, these potentials and DNA telomere
length as well are compromised, suggesting a decreased self-
renewal capacity and early apoptosis. Interestingly, after mas-
sive weight loss, there is reduced DNA damage and an
improvement of cell viability and replicative lifespan [113].
Obesity characterized by high BMI negatively affects not only
AT-MSCs but also BM-MSCs, showing severely impaired osteo-
genic and diminished adipogenic differentiation, decreased
proliferation rates, increased senescence, and elevated expres-
sion of endoplasmic reticulum stress–related genes. This may
have a direct impact on their use, particularly in the field of
regenerative medicine, where these cells could be potentially
used for the treatment of orthopedic issues. It is conceivable
that stem cells, obtained from very overweight donors,
may display severe differentiation and proliferation defects,
resulting in an isolated stem cell product of poor quality and
decreased regenerative potential in vivo [114]. An abnormal
increase in fat mass results in dysfunctional AT, and conse-
quently, AT-MSCs are defective in differentiation, pro-angio-
genesis, motility, immunomodulation, and development of
primary cilia, which are shortened and unable to properly
respond to stimuli [115, 116]. AT can also be affected by lip-
odystrophic syndromes, rare and heterogeneous disorders
characterized by an anomalous distribution of body fat or a
generalized loss of AT and variable degrees of insulin resis-
tance. In particular, in lamin-linked lipodystrophies, adipose
MSCs show a reduced differentiation and proliferation capac-
ity, premature senescence and an altered gene expression pro-
file related to lipid metabolism [117, 118]. However, maternal
obesity can also affect UC-MSCs, altering the metabolic envi-
ronment in utero. Thus, UC-MSCs from obese donors show
slower PD and a stronger immunosuppressive activity, which is
critical for heterologous clinical applications [119].
In addition, MSCs can be impaired due to more local/focused
disorders targeting a particular organ from where the cells are
harvested, impacting cell performance and compromising their
regenerative ability in an autologous and also allogeneic setting.
BM is currently the most used source of MSCs; however, various
diseases could affect this tissue, such as severe aplastic anemia,
a rare but potentially life-threatening disease, which is a para-
digm of BM failure syndromes [120]. The immune-mediated
destruction of HSCs is considered a key factor, but MSCs also dis-
play a poor potential for proliferation and adipogenic and osteo-
genic differentiation. BM-MSCs are also implicated in the biology
of splenic marginal zone lymphoma, where BM is frequently infil-
trated by the malignant cell population. Cells show impaired
growth potential and an increased DT, which could be attributed
to increased apoptosis [121, 122]. Another rare pathological con-
dition that affects BM is Shwachman-Diamond syndrome (SDS),
a rare multi-organ recessive disease mainly characterized by pan-
creatic insufficiency, skeletal defects, short stature and BM fail-
ure. MSCs derived from SDS patients show a defective ability to
form capillary tubes and vessels and display a marked decrease
in Vascular Endothelial Growth Factor A expression, together
with an inability to recreate a functional BM niche [123].
Teeth-derived MSCs could represent an alternative source
of autologous cells after the extraction of a compromised tooth,
considering the impact of the related condition. In the case of
inflamed periodontal ligaments of periodontally compromised
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teeth, MSCs show an increased proliferation capacity and migra-
tion potential; however, they are characterized by a decreased
capacity for osteogenic differentiation [80]. Similarly, inflamed
dental pulp causes a decreased PD in DPSC, so inflammation
may affect the total number of cell divisions [124].
Similarly, eMSCd are influenced by endometriosis condition.
Menstrual blood-derived stromal cells from woman with endo-
metriosis are morphologically different from healthy patient-
derived MSCs and show a higher proliferation and invasion
capacity and a greater potential to direct the inflammatory
responses in their favor, thereby facilitating the development of
endometriosis [125]. This makes them similar to cancer cells; in
fact, endometriosis patients have been reported to be more
prone to the development of ovarian cancer.
There may also be donor-related MSCs variability based on
on-going treatments. The administration of immunosuppressive
drugs, such as tacrolimus, is fundamental after organ transplan-
tation, but it can compromise the viability and proliferative abil-
ity of progenitors in a dose-dependent manner [126]. Similarly,
tamoxifen, an antitumor drug used in breast cancer, shows a
dose- and time-dependent influence on in vitro adipose-derived
progenitors, resulting in apoptosis, inhibition of proliferation
and differentiation [127]. Other chemotherapeutic agents may
have a conflicting impact on MSCs [128–130]. Similarly, radio-
therapy is used to treat various malignancies. However, it can
also adversely impact normal tissues and MSCs, causing prema-
ture senescence or accelerated terminal differentiation [131].
Collectively, these data indicate that an autologous-based strat-
egy in oncology may be extremely challenging, particularly
when there is a demand for a substantial number of stem cells.
Similarly, the prolonged use of morphine therapeutically
administered to relieve pain, impairs angiogenesis and the
activation of endothelial progenitor cells. Furthermore, mor-
phine affects MSCs proliferation and differentiation in a dose-
dependent manner and causes changes in the phenotype,
growth properties and secretory functions of MSCs, having a
negative impact on wound repair [132].
All these variabilities suggest the need for developing a
personalized approach for patients, considering their age and
comorbidities, even with pretreatment or modifications of stem
cells. Furthermore, cell dose or cell delivery may be adapted to
state of illness, type of MSCs and condition of the patient [133].
ISOLATION PROCEDURES MATTER
The challenges relative to MSCs may also be related to differ-
ent protocols for MSCs isolation. Accordingly, standardization
is difficult to be achieved, also accounting for the different tis-
sue sources and variability in the amount of starting raw mate-
rial and in relation to protection of intellectual property rights.
However, each of the early isolation steps can have an impact
on quantity and quality of ex vivo isolated cells. A conven-
tional procedure to select MSCs is based on their capacity to
adhere to plastic after an appropriate isolation method, whose
choice is still a critical step in obtaining MSC preparations for
both preclinical and clinical uses. Isolation methods are classi-
fied into four categories: enzymatic, mechanical, explant cul-
ture and density-gradient centrifugation methods.
The most common approach is the digestion of tissue
by enzymes, such as collagenase, trypsin, and dispase, which
consists in incubation at 37C for at least 1 hour, generally with
mixing. Depending on the tissue to be digested and the protocol
adopted, differences can be found in the number of washing
steps, enzyme concentration, centrifugation parameters, erythro-
cyte lysis methods to reduce hematopoietic contamination and
final filtration to remove tissue fragments [134, 135]. Sutradhar
et al. showed that trypsin–EDTA, used to detach cells from the
plastic surface, causes loss of membrane integrity and a decrease
in cell viability in a time-dependent manner [136]. For more rea-
sons, digestion time periods longer than 5 minutes can affect cell
surface antigens [137], cell surface topography, cytoskeletal com-
ponents and distribution of intramembranous particles [138] and
compromise cell isolation success. Since the use of enzymes is
characterized also by high costs and an impact on vitality and cell
yield, mechanical methods have been investigated, using shear
force, centrifugal force, radiation force, and pressure. However,
these non-enzymatic approaches are similarly variable, according
to protocols and methods [135].
Over the last years, several mechanical approaches have
been introduced to standardize the isolation process of MSC
precursors, particularly from AT. For example, new technology
guarantees shorter procedure times in a rapid and disposable
device, where AT-MSC precursors can be isolated [139, 140].
On the other hand, explant culture methods show several
advantages compared with enzymatic and mechanical isola-
tion, such as reduced cost and risk of biological contamination,
a more homogenous cell population and less cell damage, with
a consequent higher proliferation rate of MSCs. Cells are trans-
ferred from in vivo to in vitro conditions with a fragment of
tissue without the separation stress on cells [141]. Despite the
cost advantage, the success of this method depends mainly on
the manual skills of operator and quantity of starting material,
making it not always reproducible. In addition, undesired cellu-
lar elements may be carried over in culture, generating a con-
tamination that could become an important issue for MSCs
preparation release.
One of the ways to better purify the starting MSC prod-
ucts and the common method used for BM-MSCs isolation
remains the density-gradient centrifugation method. Most
preclinical and clinical studies use Ficoll-Paque as density
medium to enrich the mononuclear cell population and the
rare progenitor cells. However, Percoll density medium is
alternatively used because of its lower cytotoxicity. Still, an
important limitation of these density-based methods is the
lack of a high resolution in distinguishing stem cells and
nonstem cells, where their size difference is not absolute
[142]. Nevertheless, given the low concentration of stem
cells within a given tissue, it is generally possible to distin-
guish them from the other cell populations, using specific
cell markers on their surface. Obviously, some markers are
common between more cell types, so a combination of dif-
ferent markers is the best choice to isolate the cell popula-
tion of interest. Also, little difference in density may affect
the quality of MSCs type, as we have previously seen in
comparing Ficoll-Paque of 1.073 versus 1.077 g/ml [143].
Magnetic-activated cell sorting, MACS, is the most com-
monly used method of sorting cells by magnetic forces. Mag-
netic beads are generally coated with a specific antibody for
desired cells and passing through a magnetic field, only
antibody-bound cells are retained. Cells are finally recovered by
enzymatic detachment from the magnetic beads [144]. Another
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purification method is flow cytometry using FACS instruments,
based on the positive identification of cell surface markers
expressed by MSCs. However, the lack of knowledge of unique
markers for different cell types is an important limitation for
this method, together with the possibility of cell contamination
during the sorting phases and physical stress caused by probes,
laser damage and osmotic stress on cells [145]. Both techniques
are based on adherent cell purification and their detachment
from the plastic surface is a critical step, considering that enzy-
matic dissociation can lead to proteolytic damage of cell surface
proteins.
Once MSCs are isolated using different approaches, the
number of cells from the primary culture is often insufficient
for clinical application, especially when more systemic infu-
sions are necessary. For this reason, cell expansion is essential
to reach an appropriate number of MSCs. Cell culture variables
include medium formulation (basal media and supplements),
culture surface substrate, cell seeding density, physiochemical
environment (dissolved oxygen and carbon dioxide concentra-
tions, temperature, pH, osmolarity, and buffer system), along
with subculture protocols [146].
The literature suggests that seeding density has an impact
on cell proliferation rate. Both and collaborators described a
faster proliferation rate when MSCs were seeded at lower den-
sities [147]. However, the recommended seeding density for
BM-MSCs is 5,000 to 10,000 cells per cm2.
Cell expansion requires enzyme dissociation and cell subcul-
ture. The evaluation of the optimal cell confluence is operator-
dependent, although 70%–80% confluence is recommended to
be reached before detachment. Furthermore, repeated cell pas-
sages are necessary to obtain a sufficient number of cells and
the optimal passage to use depends on the intrinsic proliferative
ability of the cell sample. Wagner et al. reported that when
expansion is protracted for 43–77 days of cultivation, MSCs show
senescence aspects with morphological abnormalities, enlarge-
ment, attenuated expression of specific surface markers, arrested
proliferation, and also the loss of differentiation capacity [148].
In addition, telomere length decreases [149] as well as their
migratory capacity [150].
To achieve a cell dose-dependent efficacy of the treatment
in a clinical trial, a minimum of 1.5–6 × 107 cells per single dose
is required [151, 152]. Therefore, large production processes to
obtain this number of MSCs are needed, given that the increase
in incubator occupancy, handling time for culture monitoring,
and risk of contamination make two-dimensional supports inade-
quate. The success of the final product is related to the robust-
ness, reproducibility, and efficacy of the Good Manufacturing
Practice (GMP) process [153]. Different bioreactors with auto-
mated controls can guarantee a homogeneous distribution of
nutrients in the culture medium and meet the challenge of
extensive ex vivo cell expansion. Bioreactors enable the monitor-
ing of various parameters (pH, pO2, pCO2) and, hence, allow
ensured cultivation under well-controlled and reproducible con-
ditions. MSCs expansion in the rotation bed bioreactor provides
a high number of cells, maintaining their stem cell properties
such as specific surface markers, proliferation capacity and differ-
entiation potential [154].
Among cell culture variables, the choice of a well-formulated
culture medium for both isolation and expansion of MSCs is
a critical aspect. Cells require a basal medium supplemented
with proteins, growth factors, and enzymes to support cell
attachment and proliferation. Human MSCs can be grown in a
variety of medium formulations, such as Dulbecco’s modified
Eagle’s medium (DMEM) or alpha minimal essential medium
(α-MEM). DMEM is commonly used by most groups for MSCs
expansion, and furthermore, over the last years, some studies
have also demonstrated that the use of α-MEM as basal medium
has better performance in MSCs expansion and osteogenic dif-
ferentiation, compared with DMEM basal medium [147].
Basal medium is typically supplemented with 10% to 20%
FBS, which is considered essential for good proliferation of all
fibroblast cultures including BM-derived stromal cells. How-
ever, the use of animal-derived serum is not the best choice
for clinical applications because of the risk of the transmission
of infections, associated with pathogens such as viruses,
prions, mycoplasma or other zoonotic agents. Furthermore,
the high content of xenogeneic proteins could be associated
with immune reactions in patients in MSCs translation to the
clinic and with respect to GMP, the high degree of batch-to-
batch variation is not compatible with the need for reproduc-
ibility [146]. To overcome these regulatory concerns, human
autologous serum has been introduced in MSCs expansion
[155], although it is difficult to obtain a sufficient amount for
supporting the growth of great numbers of MSCs, and its ben-
eficial effect may decrease with age, becoming nonapplicable
in elderly patients.
More recently, many studies have reported the use of
human platelet lysate (PL), prepared by lysis of the platelet
membrane, as an alternative source of growth factors and a
valid substitute for FBS. It is easily obtained from autologous
peripheral blood with a large quantity and minimal donor site
morbidity [156]. PL has been reported to have a positive influ-
ence on MSCs proliferation and osteogenic differentiation,
being a natural reservoir of cytokines and growth factors
[157], helpful in tissue engineering approaches.
In addition, several serum-free media have been devel-
oped, but the omission of serum, which is a complex fluid rich
in biological factors, nutrients, growth factors, antitoxins and
much more, requires many supplements for cell survival and
proliferation [146]. The optimization of defined serum-free
medium for a specific cell type is very difficult and influenced
by multiple variables regarding cell characteristics. Serum func-
tions can be replaced by supplements such as binding proteins
(i.e., albumin, transferrin), additional nutrients (i.e., lipids, vita-
mins, amino acids), physiochemical reagent (i.e., buffer), hor-
mones (i.e., insulin), growth factors (i.e., Platelet-Derived
Growth Factor, Epidermal Growth Factor, Fibroblast Growth
Factor) and attachment factors [158, 159].
WHY MSC FUNCTIONS DO NOT SOLIDLY SHIFT THEM TOWARD
CLINIC YET?
The enthusiasm around MSC properties, together with ease of
isolation and ex vivo expansion, reinvigorated a global interest
in MSCs with an increasing number of clinical studies. In January
2019, a search on the public website clinicaltrial.gov, using as
keywords “MSC,” “mesenchymal cells,” “stromal cells,” resulted
in more than 900 registered studies worldwide. A more careful
look revealed that most of these MSC-based trials are still in
early phases I or II, while only a small portion of them (less than
50) are in phase III [98], and currently, only nine products
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(approximately 1%) have been approved worldwide for market
authorization [160]. This should be seen as unexpected for a
50 year-old cell type, particularly considering that both local
and intravascular MSC infusions have been considered relatively
safe procedures [161].
One of the possibilities to explain this is related to the
type of disease that is meant to be cure by MSCs. In several
cases these cells are transplanted for rare incurable congenital
disorders that may not have the numbers to fit the require-
ment of phase III studies [162]. On the other hand, when the
number of patients might be suitable, the results may not fully
meet the endpoints due to inclusion criteria that may deal
with extremely advanced diseases where the MSC therapeutic
effects may not be fully manifested due to improper microen-
vironmental stimuli or just because the potential benefit is
unbalanced versus the severity of the conditions.
Finally, there are human diseases where the responsible path-
ophysiological event is yet unclear and researchers have
attempted to introduce MSCs on the basis of a working hypothe-
sis. That is the case with neurodegenerative disorders that are dra-
matically widespread and include multiple sclerosis, amyotrophic
lateral sclerosis, Parkinson’s disease, Huntington’s disease, spinal
cord injury, and Alzheimer disease. MSC-based therapy is actually
considered one of the most promising treatment for these disabil-
ities; however, the observed effects might be only marginally asso-
ciated with MSCs differentiation into functional neural cells
[163–165]. These early beneficial effects of MSCs reported in pilot
clinical studies may be derived from their stromal action, through
the secretion of neural growth factors, although the precise mech-
anism of neural tissue repair is still unclear.
These controversial successes in neurodegenerative disease
treatment might have also arisen from the way in which MSCs
are delivered [166, 167]. When possible, local implantation with
direct application into the injured site may be preferable for tis-
sue defects. However, most MSCs target diseases are systemic,
and intravenous administration of MSCs is then required. This
is linked to cell biodistribution and to the questions regarding
the number of cells reaching the injured site. It was originally
suggested that the majority of intravenously administered MSCs
are trapped in the lungs, as the first organs encountered, and
subsequently in other tissues, consequently resulting in a reduced
therapeutic profile [168, 169]. Other investigations very recently
described how pulmonary trapping is followed by phagocytosis of
MSCs by monocytes, which subsequently migrate from the lungs
to other body sites, modulating cells of the adaptive immune sys-
tem and still providing a therapeutic impact [170]. Along the
same line, it has been demonstrated that infused apoptotic MSCs
can act together with monocytes to promote immunosuppression
in an animal model of graft versus host disease [171]. Collectively,
MSC-based pharmacological developments are still missing robust
pharmacodynamic and pharmacokinetic models to be applied in
the different clinical situations [172, 173]. This surely calls for ad
hoc investigations able to reflect the complexity of these cell
types, their interactions with host cells and diseases in which they
are applied.
Systemic administration of MSCs is one of the proposed
treatments in regenerating different damaged tissues, such as
myocardium [174, 175], basing its action on the ability of MSCs
to home to the injured site, driven by the interaction with
chemokines and cytokines. The ease and low invasiveness of the
approach represents an advantage in the treatment of different
dysfunctions which require repeated injections of stem cells to
obtain a therapeutic effect [176]. A remarkable clinical interest
has been developed over the years with reference to cardiac
dysfunctions. The excessive immune/inflammatory responses,
which contribute to the progression of acute myocardial infarc-
tion and ischemic cardiomyopathy, can be controlled by the anti-
inflammatory effects of MSCs [175]. The exact mechanism of
action is not clear, but the idea that paracrine signals could play
a key role in cardioprotection has taken hold, especially in myo-
cardial infarction, where the increase in neoangiogenesis and
vascularization is decisive [177]. Differently from the brain, the
heart is well known and studied, and numerous data have been
collected from animal models. The promising results with
infarcted murine hearts, where injected MSCs became function-
ally integrated with the surrounding native myocardium, have
contributed to the increased expectations for MSCs differentia-
tion into cardiomyocytes. Despite the numerous preclinical and
clinical studies conducted, the contradictory data approximately
the efficacy of cell therapy in cardiac function improvement
require a better understanding of MSCs source, delivery manner
and cell doses to overcome the limitations of the therapeutic
approach [178]. Their positive effect may occur via a paracrine
action thanks to numerous angiogenic, arteriogenic, chemotactic,
and antiapoptotic growth factors.
Site-directed delivery might be more feasible in tissue engi-
neering, where cells can be locally implanted in association with
biomaterials, avoiding the first passage time distribution via
blood circulation. This significantly enhances homing of MSCs to
the injury site compared with distant intravenous injection. One
example of this approach is related to skeletal regeneration
where MSCs can be applied with or without supportive bioma-
terial. In the field of orthopedic regeneration, there are data
that support the beneficial effect of MSCs treatment in menis-
cus, intervertebral disc, ligament, and tendon or muscle injuries
[179]. The particular interest around bone defects, which are
often associated with a substantial morbidity, has led to a clini-
cal implementation of bone regeneration approaches, such as
for osteoarthritis [180], osteonecrosis, nonunion bone defects
[181], infantile hypophosphatasia [182], osteoporosis [183], and
bone fractures [184]. This has been also happening for rare and
very severe skeletal diseases such as for osteogenesis imper-
fecta (OI) even with intravenous injection. OI is a prenatal
genetic deadly disorder characterized by bone fragility, bone
deformity, and frequent fractures mainly caused by a defect of
collagen genes. OI treatment with intravenously delivered MSCs
has been pioneeristically performed by Horwitz group indicating
feasibility although associated with transient efficacy [185, 186]
that opened novel hypothesis on how MSCs may repair skeletal
tissues after systemic injection [187].
BUSINESS, COSTS, AND MSCS CLINICAL TRANSLATION
Despite the development and the interest in MSC-based ther-
apy and its clinical potentials, few human MSC-based products
have been authorized for market and used in clinics worldwide
[160]. Many challenges remain, including the need for more
harmonized regulatory frames among countries to facilitate
from early developments to large multinational trials.
Clinical translation cannot be realized without also consider-
ing investor expectations in relation to the product potential and
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its possible therapeutic impact. For this reason economic factors
have been also influencing the field: when an MSC-based product
has been showing a valid safety and therapeutic profile, corpo-
rate investments raise making product available for many [188].
However, when product retains uncertainties that are not chal-
lenged within adequate preclinical models followed by well-
designed clinical trials, venture capital and big pharma may be
generally reluctant to invest. Thus, it is key to reach a comfort
zone in the R&D package since the early steps of development to
be properly validated before transferring tasks to a clinical-grade
development. This calls also for attention related to the transition
between preclinical and clinical developments in terms of reagent
use and procedures. If applicable, cGMP implementation has to
be considered during preclinical product characterization to avoid
being trapped in the translation process. In addition, we feel that
possible massive corporate investments in MSC-based therapies
have been also hindered by the fear that similar academic-
based products can be used in patients as part of a consolidated
clinical practice and/or can be produced within hospital-based
manufacturing facilities impacting on the possible revenues. In
this sense a clearer interaction in the relationship between pub-
lic hospital/academia and private sector is requested under the
umbrella of regulatory agencies within defined reimbursements
policy and in the respect of intellectual property protection.
A strong MSCs therapy clinical translation cannot be realized
without considering the relevant aspects of the product cycle
and its related cost. Currently, the costs of MSCs manufacturing
vary between 15,000 and 30,000 $/€ per 1–5 million cGMP-
MSCs per kilogram [189, 190]. These manufacturing costs then
have to be added to the expenses related to the clinical delivery
and the follow up. In addition, when a gene vector has to be
included in the manufacturing, numbers considerably increase.
Although for a life-saving cell-based strategies a cost over
100,000 $/€ may be well tolerated [191], for treatments coun-
teracting diseases with an impact in quality of life these number
may be questionable by either private or public reimbursement
bodies. This has been an aspect that additionally impacted on
the solid translation of MSCs toward clinic. Therefore, efforts
have to be made in minimizing the cost per unit of cells and ulti-
mately the cost per treatments, while maintaining product qual-
ity. This could have a disruptive impact on the clinical need in
particular for allogeneic MSCs therapy, which is a more commer-
cially attractive option because it provides cells ready-to-use for
many patients [192]. In this scenario, the mentioned MSCs bio-
logical factors (i.e., tissue source, donor variability) have to be
accounted since they may have a profound impact on
manufacturing processes due to the expansion potential of the
cells that is directly tied to the cost of production. Many efforts
have been focused on the development of novel expansion tech-
nologies, to meet the needs of substantial cell numbers and the
creation of a robust cell bank to supply cells for large number of
recipients [193]. The introduction of bioreactors providing bil-
lions of cells with consistent product quality and reproducibility
has been recently proposed with promising results. Furthermore,
clinically approved alternatives to animal sera for cell culture also
based on blood-derived materials, such as PL, and recombinant
media have been successfully introduced. However, this may not
be enough and a significant reduction of manufacturing costs will
come from the decrease in quality control testing expenses con-
ceiving novel assays that would maintain product quality while
reducing the price and time for execution.
CONCLUSIONS AND FUTURE PERSPECTIVES
The excitement around MSCs research increased since their early
identification generating a relatively rapid clinical translation.
This promising race, that sounded like a possible solution for
many diseases, clashed with evidence of a suboptimal perfor-
mance. Future MSC-based preclinical and clinical investigations
should take into account a variety of issues that we here wanted
to emphasize. In particular, considering (a) donor-related fea-
tures (age and comorbidities) that may impact on the quantity
and quality of obtainable cells; (b) a better identification of the
precise beneficial mechanism/s of action calling for ad hoc inves-
tigations also able to dissect MSCs complexity (i.e., stromal ver-
sus stem) and their interactions with host tissues; (c) the
development of more robust pharmacodynamic and pharmaco-
kinetic models to be applied in the different clinical situations;
and (d) a selection of reagents and procedures that may be
applied from preclinical to clinical developments aimed to main-
tain cell consistency and ultimately reduce manufacturing costs.
To conclude, this review points out MSC strengths and weak-
nesses in order to generate a better awareness on the challenges
that should be taken into account for more performing MSC-
based therapeutics.
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